Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRX-0405 in advanced solid tumors
NCT06710379Phase 1Recruiting
- Sponsor
- Adcentrx Therapeutics
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADRX-0405 in metastatic castration-resistant prostate cancer (mCRPC), gastric cancer (GC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Adcentrx Therapeutics. Primary endpoint: Incidence of adverse events up to 2 years. Started Dec 2024; status: recruiting.
02
Drugs
ADRX-0405
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)gastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06710379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710379.